Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

36.88 +0.12 (+0.33%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products. 
Via Benzinga
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. 
Via InvestorPlace
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
If approved, this would be the first combination vaccine based on mRNA technology to hit the market. 
Via Investor's Business Daily
Exposures COVID-19
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
From GSK plc
Via Business Wire
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines. 
Via InvestorPlace
Topics Economy
Exposures Economy
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
GSK Stock Falls as 70,000 Zantac Lawsuits Move Forward. What to Know.
Investors in GlaxoSmithKline are seeing a lot of red on their screens today, as GSK stock falls more than 8% on big legal news. 
Via InvestorPlace
Topics Lawsuit
Exposures Financial Legal
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a significant improvement in progression-free survival for relapsed or... 
Via Benzinga
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
From GSK plc
Via Business Wire
Is Moderna Stock a Buy Now That It's a 2-Product Company?
The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response. 
Via The Motley Fool
Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
From GSK plc
Via Business Wire
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
Moderna's RSV vaccine will launch a year behind Pfizer and GSK, but it could become the market leader over the next five years. 
Via Investor's Business Daily
Exposures Product Safety
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers. 
Via Benzinga
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements. 
Via Benzinga
GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. This follows Valisure's 2019 tests showing Zantac forms a carcinogen,... 
Via Benzinga
Topics Lawsuit Whistleblower
Exposures Financial Legal
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
GSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe asthma exacerbations. 
Via Benzinga
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers. 
Via Benzinga
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet. 
Via InvestorPlace
Amazon Pours ~$1.3B Investment Into French Operations: Report
Amazon's €1.2 billion investment marks a significant stride in bolstering its French presence, promising 3,000 new jobs. The move aligns with France's push for tech investment, showcased at the 'Choose... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported. 
Via Benzinga
Exposures Product Safety
Moderna Dives Back Into Buy Zone After FDA Delays Its RSV Vaccine
The FDA hasn't said there are any vaccine effectiveness, safety or quality issues that would prevent approval, Moderna says. 
Via Investor's Business Daily
Exposures Product Safety
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.